Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ranibizumab PRN versus aflibercept bimonthly for wet age-related macular degeneration
2013-002431-15Phase 4Completed
- Sponsor
- Novartis
- Start
- Jul 2013
- Modality
- Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial in exudative macular degeneration comparing Ranibizumab PRN with Aflibercept bimonthly (2 arms). Primary endpoint: Central subfield retinal thickness stability. Started Jul 2013; status: completed.
02
Drugs
ranibizumabaflibercept
03
Conditions
exudative macular degeneration
Beyond the preview
Go deeper on 2013-002431-15.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-002431-15.